tradingkey.logo
tradingkey.logo
Suchen

Valneva SE

VALN
Zur Watchlist hinzufügen
5.680USD
-0.260-4.38%
Handelsschluss 05/15, 16:00ETKurse um 15 Minuten verzögert
545.56MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Valneva SE Unternehmen

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Valneva SE Informationen

BörsenkürzelVALN
Name des UnternehmensValneva SE
IPO-datumJun 28, 2007
CEOLingelbach (Thomas)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeJun 28
Addresse6, Rue Alain Bombard
StadtSAINT-HERBLAIN
BörseNASDAQ OMX - NASDAQ BASIC
LandFrance
Postleitzahl44800
Telefon33228073710
Websitehttps://valneva.com/
BörsenkürzelVALN
IPO-datumJun 28, 2007
CEOLingelbach (Thomas)

Führungskräfte von Valneva SE

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
IXIARO
98.42M
56.35%
DUKORAL
31.91M
18.27%
Third party products
19.16M
10.97%
R&D
9.98M
5.72%
IXCHIQ
8.42M
4.82%
Andere
6.77M
3.87%
Nach RegionUSD
Name
Umsatz
Anteil
United States
53.61M
30.69%
Canada
30.13M
17.25%
Germany
17.47M
10.00%
France
14.67M
8.40%
Nordics
13.90M
7.96%
Andere
44.89M
25.70%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
IXIARO
98.42M
56.35%
DUKORAL
31.91M
18.27%
Third party products
19.16M
10.97%
R&D
9.98M
5.72%
IXCHIQ
8.42M
4.82%
Andere
6.77M
3.87%

Aktionärsstatistik

Aktualisiert: Thu, May 7
Aktualisiert: Thu, May 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Novo Holdings A/S
2.43%
Frazier Life Sciences Management, L.P.
2.42%
General American Investors Company, Inc.
0.37%
Wells Fargo Advisors
0.08%
Morgan Stanley & Co. International Plc
0.03%
Andere
94.66%
Aktionäre
Aktionäre
Anteil
Novo Holdings A/S
2.43%
Frazier Life Sciences Management, L.P.
2.42%
General American Investors Company, Inc.
0.37%
Wells Fargo Advisors
0.08%
Morgan Stanley & Co. International Plc
0.03%
Andere
94.66%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
2.44%
Private Equity
2.42%
Investment Advisor
0.43%
Research Firm
0.17%
Hedge Fund
0.02%
Andere
94.51%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
36
5.21M
5.50%
-309.16K
2025Q4
32
5.27M
6.14%
+505.55K
2025Q3
30
4.53M
5.58%
+3.61M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Novo Holdings A/S
2.31M
2.66%
-40.00K
-1.71%
Dec 31, 2025
Frazier Life Sciences Management, L.P.
2.29M
2.64%
--
--
Dec 31, 2025
General American Investors Company, Inc.
354.36K
0.41%
--
--
Dec 31, 2025
Wells Fargo Advisors
123.46K
0.14%
-30.53K
-19.82%
Dec 31, 2025
Morgan Stanley & Co. International Plc
32.26K
0.04%
+9.49K
+41.70%
Dec 31, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
--
--
Dec 31, 2025
Citadel Advisors LLC
23.49K
0.03%
+7.08K
+43.17%
Dec 31, 2025
Morgan Stanley Smith Barney LLC
10.70K
0.01%
+500.00
+4.90%
Dec 31, 2025
XTX Markets LLC
10.63K
0.01%
+10.63K
--
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI